NASDAQ:BLRX

BioLineRx (BLRX) Stock Forecast, Price & News

$1.66

+0.04 (+2.43%)

(As of 02:29 PM ET)

Compare

Today's Range: $1.59
▼
$1.68
50-Day Range: $0.79
▼
$1.65
52-Week Range: $0.55
▼
$1.98

Volume: 173,742 shs
Average Volume: 402,673 shs
Market Capitalization: $102.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

BioLineRx MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 270.4% Upside
$6.00 Price Target
Short Interest: Bearish
3.17% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -1.17
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.69) to ($0.55) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

832nd out of 983 stocks

Pharmaceutical Preparations Industry

416th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, BioLineRx has a forecasted upside of 270.4% from its current price of $1.62.
Amount of Analyst Coverage
BioLineRx has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.17% of the outstanding shares of BioLineRx have been sold short.
Short Interest Ratio / Days to Cover
BioLineRx has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in BioLineRx has recently increased by 69.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioLineRx does not currently pay a dividend.
Dividend Growth
BioLineRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLRX.

1.0

News and Social Media Coverage

News Sentiment
BioLineRx has a news sentiment score of -1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for BioLineRx this week, compared to 2 articles on an average week.
Search Interest
33 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 74% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLineRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.10% of the stock of BioLineRx is held by insiders.
Percentage Held by Institutions
Only 18.15% of the stock of BioLineRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioLineRx are expected to grow in the coming year, from ($0.69) to ($0.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLineRx is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLineRx is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLineRx has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

May 30, 2023 | americanbankingnews.com

Analysts Offer Predictions for BioLineRx Ltd.'s Q2 2023 Earnings (NASDAQ:BLRX)

May 24, 2023 | finance.yahoo.com

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 23, 2023 | seekingalpha.com

biolinerx Q1 2023 Earnings Preview

May 21, 2023 | americanbankingnews.com

BioLineRx (NASDAQ:BLRX) Earns Sell Rating from Analysts at StockNews.com

May 17, 2023 | finance.yahoo.com

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

May 10, 2023 | investing.com

BioLine RX Ltd (BLRX)

April 25, 2023 | finance.yahoo.com

BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 2, 2023 | Edge On The Street (Ad)

Is Graphite the New Lithium?

Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.

April 23, 2023 | americanbankingnews.com

BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average of $0.73

April 17, 2023 | finance.yahoo.com

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma

March 29, 2023 | americanbankingnews.com

BioLineRx Ltd. Forecasted to Earn Q1 2023 Earnings of ($0.14) Per Share (NASDAQ:BLRX)

March 28, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for BioLineRx Ltd. (NASDAQ:BLRX) Cut by Analyst

March 24, 2023 | finance.yahoo.com

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript

March 24, 2023 | americanbankingnews.com

BioLineRx (NASDAQ:BLRX) Given "Buy" Rating at HC Wainwright

March 23, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Bioline RX Ltd Sponsored ADR (BLRX)

March 23, 2023 | finance.yahoo.com

BLRX: Confidence in a Strong Launch

March 22, 2023 | finance.yahoo.com

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates

March 20, 2023 | sg.finance.yahoo.com

BioLineRx Ltd. (BLRX.TA)

March 15, 2023 | finance.yahoo.com

BioLineRx to Report 2022 Annual Financial Results on March 22, 2023

March 12, 2023 | finance.yahoo.com

BioLineRx Ltd. (BLRX) Stock Historical Prices & Data - Yahoo Finance

March 6, 2023 | finance.yahoo.com

BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

March 4, 2023 | prnewswire.com

BLRX MONDAY DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

March 3, 2023 | businesswire.com

BIOLINERX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm

March 3, 2023 | businesswire.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)

February 11, 2023 | prnewswire.com

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

February 4, 2023 | prnewswire.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

See More Headlines

BLRX Price History

30 days | 90 days | 365 days | Advanced Chart

BLRX Company Calendar

Last Earnings: 3/22/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/15/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLRX
CUSIP: N/A
CIK: 1498403
Web: www.biolinerx.com
Phone: (728) 642-9100
Fax: 972-8642-9101
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +270.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,950,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.71%
Return on Assets: -43.71%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 3.68
Quick Ratio: 3.68

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.64 per share
Price / Book: 2.53

Miscellaneous

Outstanding Shares: 61,531,000
Free Float: 60,854,000
Market Cap: $99.68 million
Optionable: Not Optionable
Beta: 1.89

Key Executives

Philip Adam Serlin
Chief Executive Officer

Mali Zeevi
Chief Financial Officer

Irit Gliko-Kabir
Vice President-Clinical Operations

Tami Rachmilewitz
Chief Medical Officer

Ella Sorani
Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLRX Stock - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings or view top-rated stocks.
What is BioLineRx's stock price forecast for 2023?: 1 Wall Street research analysts have issued twelve-month price objectives for BioLineRx's stock. Their BLRX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price.
View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts.
How have BLRX shares performed in 2023?: BioLineRx's stock was trading at $0.59 at the beginning of the year. Since then, BLRX stock has increased by 174.6% and is now trading at $1.62.
View the best growth stocks for 2023 here.
Are investors shorting BioLineRx?: BioLineRx saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,950,000 shares, an increase of 69.6% from the April 30th total of 1,150,000 shares. Based on an average daily volume of 489,900 shares, the days-to-cover ratio is presently 4.0 days.
View BioLineRx's Short Interest.
When is BioLineRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 15th 2023.
View our BLRX earnings forecast.
How were BioLineRx's earnings last quarter?: BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings data on Wednesday, March, 22nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05.

What other stocks do shareholders of BioLineRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).
What is BioLineRx's stock symbol?: BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."
Who are BioLineRx's major shareholders?: BioLineRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (3.70%), Renaissance Technologies LLC (0.17%) and Envestnet Asset Management Inc. (0.16%).
How do I buy shares of BioLineRx?: Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioLineRx's stock price today?: One share of BLRX stock can currently be purchased for approximately $1.62.
How much money does BioLineRx make?: BioLineRx (NASDAQ:BLRX) has a market capitalization of $99.68 million. The biotechnology company earns $-24,950,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.
How can I contact BioLineRx?: BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial